PolyPid Ltd. (PYPD)

PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data

PolyPid Nears FDA Decision for D-PLEX100 After Strong Phase III Data

European Medicines Agency Validates PolyPid's Marketing Authorization Application for D-PLEX₁₀₀

PolyPid Regains European Commercialization Rights for D-PLEX₁₀₀, Expanding Global Commercialization Opportunities

PolyPid Announces Participation in Upcoming Fall Investor Conferences

PolyPid Ltd. (PYPD) Q2 2026 Earnings Call Transcript

PolyPid Q2 Earnings Call Highlights

PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results

PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026

PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀

PolyPid, Azurity sign surgical site infection drug deal

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada

PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada